Candel Therapeutics Files 8-K with Corporate Updates

TL;DR

Candel Therapeutics filed an 8-K on 5/29, updating bylaws and filing financials.

AI Summary

Candel Therapeutics, Inc. filed an 8-K on May 29, 2024, reporting amendments to its articles of incorporation or bylaws and filing financial statements and exhibits. The company, incorporated in Delaware, is in the biological products sector and is headquartered in Needham, MA.

Why It Matters

This filing indicates Candel Therapeutics is making administrative changes and providing updated financial information, which is crucial for investors to understand the company's current operational and financial status.

Risk Assessment

Risk Level: low — This filing is primarily administrative and informational, with no immediate indication of significant financial or operational risk.

Key Numbers

• 1231 — Fiscal Year End (Indicates the end of the company's financial reporting year.)

Key Players & Entities

• Candel Therapeutics, Inc. (company) — Registrant
• May 29, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of Incorporation
• Needham, MA (location) — Principal Executive Offices
• 001-40629 (identifier) — Commission File Number

FAQ

Key Financial Figures

• $0.01 — nge on which registered Common Stock, $0.01 par value per share CADL The Nasdaq

Filing Documents

• cadl-20240529.htm (8-K) — 44KB
• cadl-ex3_1.htm (EX-3.1) — 14KB
• 0000950170-24-066608.txt ( ) — 181KB
• cadl-20240529.xsd (EX-101.SCH) — 29KB
• cadl-20240529_htm.xml (XML) — 5KB

03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On May 29, 2024, the Board of Directors of Candel Therapeutics, Inc. (the "Company") approved and adopted an amendment (the "Bylaws Amendment") to the Amended and Restated Bylaws of the Company (the "Bylaws"), effective immediately. The Bylaws Amendment amended Section 5 of Article I of the Bylaws to reduce the quorum requirement for all meetings of stockholders of the Company from a majority of the shares of the Company entitled to vote to one-third of the shares of the Company entitled to vote. The foregoing description of the Bylaws Amendment is qualified in its entirety by reference to the full text of the Bylaws Amendment, a copy of which is filed with this Current Report on Form 8-K as Exhibit 3.1 and incorporated herein by reference.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 3.1 Amendment to the Amended and Restated Bylaws of Candel Therapeutics, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Candel Therapeutics, Inc. Date: May 30, 2024 By: /s/ Paul Peter Tak Paul Peter Tak, M.D., Ph.D., FMedSci President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR